Prices are closing data as of 2026-11-09, not real-time quotes. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for Revolution Medicines, Inc.?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2018–2025
Key Multi-Year Facts
- Net income was negative in FY2018, FY2019, FY2020, FY2021, FY2022, FY2023, FY2024, FY2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (USD B) | 0.03 | 0.04 | 0.01 | 0.00 | 0.00 |
| YoY | -31.6% | 20.4% | -67.3% | -100.0% | — |
| Net Income (USD B) | -0.19 | -0.25 | -0.44 | -0.60 | -1.13 |
| Operating Cash Flow (USD B) | -0.15 | -0.22 | -0.35 | -0.56 | -0.90 |
| ROE | -34.7% | -38.7% | -34.7% | -29.3% | -58.1% |
| Net Margin | -636.3% | -703.8% | -3765.1% | — | — |
| Debt-to-Assets | 18.3% | 15.6% | 11.4% | 11.5% | 30.7% |
Show all 8 fiscal years
| Fiscal Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD B) | 0.02 | 0.05 | 0.04 | 0.03 | 0.04 | 0.01 | 0.00 | 0.00 |
| YoY | — | 148.2% | -14.1% | -31.6% | 20.4% | -67.3% | -100.0% | — |
| Net Income (USD B) | -0.04 | -0.05 | -0.11 | -0.19 | -0.25 | -0.44 | -0.60 | -1.13 |
| Operating Cash Flow (USD B) | 0.00 | -0.05 | -0.10 | -0.15 | -0.22 | -0.35 | -0.56 | -0.90 |
| ROE | — | — | -22.8% | -34.7% | -38.7% | -34.7% | -29.3% | -58.1% |
| Net Margin | -207.2% | -95.2% | -251.6% | -636.3% | -703.8% | -3765.1% | — | — |
| Debt-to-Assets | — | 30.8% | 16.3% | 18.3% | 15.6% | 11.4% | 11.5% | 30.7% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: SEC XBRL filings, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-10
Rules-based screening using SEC XBRL financial data and 8-K/NT material event filings (no AI opinions).
Items Flagged for Review
- Alert
-
Alert
Net LossesGoing Concern
FY2025 (2025-12-31) $-1.13B, FY2024 (2024-12-31) $-0.60B
FY2025 (ended 2025-12-31)
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
More U.S. data: 500 largest U.S. companies · U.S. high dividend stocks · Is the stock market open today?
Compiled mechanically from public filings and market quotes (data as of 2026-11-10). For informational purposes only, not investment advice.